We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Masimo (MASI), Spacelabs Team Up to Enhance Patient Outcome
Read MoreHide Full Article
Masimo Corporation (MASI - Free Report) recently extended its partnership with Spacelabs Healthcare in patient monitoring with the aim of providing better patient outcomes. The tie-up will enable Spacelabs Healthcare to integrate SET pulse oximetry, NomoLine capnography, rainbow SET Pulse CO-Oximetry, SedLine brain function monitoring and O3 regional oximetry into its select multi-parameter monitors.
For investors’ note, Spacelabs Healthcare is a division of OSI Systems, Inc. (OSIS - Free Report) and a provider of medical equipment and services.
The latest collaboration is expected to significantly strengthen Masimo’s foothold in the global patient monitoring solutions business.
Significance of the Partnership
Per Masimo’s management, the latest partnership with Spacelabs will enable it to provide advanced parameters to hospitals equipped with their innovative patient monitors. This is likely to help hospitals provide the best possible patient care. Further, management expects to aid clinicians gain more insight into their patients’ physiological status, thereby helping them improve outcomes.
Further, Spacelabs’ management believes that extending its partnership with Masimo will enable the former to integrate its patient monitoring systems with Masimo’s suite of advanced measurements to perform better patient-centric actions.
Industry Prospects
Per a report by Markets And Markets, the global patient monitoring devices market is projected to reach $55.1 billion by 2025 from $36.4 billion in 2020 at a CAGR of 8.6%. Factors like technological advancements and growing preference for telehealth services amid the pandemic are expected to drive the market.
Given the market potential, the partnership is expected to significantly boost Masimo’s business worldwide.
Recent Developments
Of late, Masimo has been witnessing few developments across its businesses.
The company, this month, announced the publication of study results in the Journal of Anesthesia & Clinical Research. The study evaluated the utility of Masimo O3 Regional Oximetry to aid in monitoring septic shock patients who have been admitted to the ICU.
The same month, Masimo announced the publication of favorable study results in the Journal of Applied Physiology. The study evaluated the usefulness of Masimo PVi as a non-invasive method of predicting preload responsiveness in patients treated with nasal high-flow therapy.
In April, the company received the FDA 510(k) clearance for its portable real-time capnograph with wireless Bluetooth connectivity, Radius PCG.
Price Performance
Shares of the company have lost 13.4% in the past year against the industry’s 13.6% rise and the S&P 500’s 44.7% growth.
The Cooper Companies’ long-term earnings growth rate is estimated at 11%.
DaVita’s long-term earnings growth rate is estimated at 14.4%.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Image: Bigstock
Masimo (MASI), Spacelabs Team Up to Enhance Patient Outcome
Masimo Corporation (MASI - Free Report) recently extended its partnership with Spacelabs Healthcare in patient monitoring with the aim of providing better patient outcomes. The tie-up will enable Spacelabs Healthcare to integrate SET pulse oximetry, NomoLine capnography, rainbow SET Pulse CO-Oximetry, SedLine brain function monitoring and O3 regional oximetry into its select multi-parameter monitors.
For investors’ note, Spacelabs Healthcare is a division of OSI Systems, Inc. (OSIS - Free Report) and a provider of medical equipment and services.
The latest collaboration is expected to significantly strengthen Masimo’s foothold in the global patient monitoring solutions business.
Significance of the Partnership
Per Masimo’s management, the latest partnership with Spacelabs will enable it to provide advanced parameters to hospitals equipped with their innovative patient monitors. This is likely to help hospitals provide the best possible patient care. Further, management expects to aid clinicians gain more insight into their patients’ physiological status, thereby helping them improve outcomes.
Further, Spacelabs’ management believes that extending its partnership with Masimo will enable the former to integrate its patient monitoring systems with Masimo’s suite of advanced measurements to perform better patient-centric actions.
Industry Prospects
Per a report by Markets And Markets, the global patient monitoring devices market is projected to reach $55.1 billion by 2025 from $36.4 billion in 2020 at a CAGR of 8.6%. Factors like technological advancements and growing preference for telehealth services amid the pandemic are expected to drive the market.
Given the market potential, the partnership is expected to significantly boost Masimo’s business worldwide.
Recent Developments
Of late, Masimo has been witnessing few developments across its businesses.
The company, this month, announced the publication of study results in the Journal of Anesthesia & Clinical Research. The study evaluated the utility of Masimo O3 Regional Oximetry to aid in monitoring septic shock patients who have been admitted to the ICU.
The same month, Masimo announced the publication of favorable study results in the Journal of Applied Physiology. The study evaluated the usefulness of Masimo PVi as a non-invasive method of predicting preload responsiveness in patients treated with nasal high-flow therapy.
In April, the company received the FDA 510(k) clearance for its portable real-time capnograph with wireless Bluetooth connectivity, Radius PCG.
Price Performance
Shares of the company have lost 13.4% in the past year against the industry’s 13.6% rise and the S&P 500’s 44.7% growth.
Zacks Rank & Key Picks
Currently, Masimo carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks from the broader medical space are The Cooper Companies, Inc. (COO - Free Report) and DaVita Inc. (DVA - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Cooper Companies’ long-term earnings growth rate is estimated at 11%.
DaVita’s long-term earnings growth rate is estimated at 14.4%.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How to Profit from Trillions on Spending for Infrastructure>>